Corbett LectureshipSOPH video/templatefiles/umc_video.aspx?id=2147548944Mannings for Health
  • Gene L. Bidwell III, PhD


    Assistant Professor (Non-clinical)
    Phone: (601) 984-6787
    Fax: (601) 984-6626

    View CV

    Areas of interest

    • Research
    • Drug delivery
    • Therapeutic peptides and proteins


    • Undergraduate
      BA in Biochemistry, University of Mississippi, Oxford, MS
    • Graduate school
      PhD in Biochemistry, University of Mississippi Medical Center, Jackson, MS
    • Postdoctoral training
      Postdoctoral Fellowship, University of Mississippi Medical Center, Jackson, MS 

    Research interests

    My research interests include targeted drug delivery, therapeutic peptides, and protein-based therapeutics.  My background and training included the development of stimulus-responsive drug carriers for targeting drugs to solid tumors. We utilized a thermally responsive carrier to target therapeutic peptides and small molecule chemotherapeutics to tumor sites using focused heating. My current research interests include engineering protein carriers for delivery of peptide and protein - based therapeutics in several disease models.

    One of our current areas of focus is drug delivery during pregnancy. We are developing carriers that can be fused to therapeutic agents, including chemotherapeutics, peptides, and proteins, that prevent them from crossing the placenta and reaching the baby. Our goal is to develop a means to treat disorders of pregnancy (such as preeclampsia), or to deliver drugs currently unsafe for use during pregnancy, to pregnant patients without risking harm to the developing fetus from drug exposure.

    A second area of interest in my lab is delivery of neurotrophic growth factors to the brain (via intranasal administration or direct focal injection) for therapy of neurological disorders. We are currently evaluating the delivery of protein carrier-fused growth factors for therapy of neurodegenerative disorders. Fusion of growth factors as a chimera with this protein carrier allows us to easily purify the agents after recombinant expression and stabilizes them for use in vivo.

    Our lab also has an interest in therapeutic angiogenesis for kidney disease. We are examining the use of carrier-fused, kidney-targeted growth factors for protection or regeneration of renal vasculature in the context of renal artery stenosis and chronic kidney disease.

    Another area of focus in our lab is developing a drug delivery system for administering therapeutics to the eye. We are working to create anti-angiogenic and anti-microbial agents that have corneal penetrating capability to treat ocular disorders such as corneal neovascularization and bacterial keratitis.